Esperas Pharma, Inc. secured a follow-on investment from TVM Capital Life Science and the Fonds de solidarité FTQ to advance its oral Check 1 inhibitor, ESP-001, targeting high-grade serous ovarian cancer.
Target Overview
Esperas Pharma, Inc. is a biotechnology firm headquartered in Montréal, Québec, dedicated to the development of innovative cancer treatments. The company's flagship compound, ESP-001 (previously known as LY2880070), is an oral Check 1 inhibitor originally discovered during a research initiative at Eli Lilly and Company. This compound shows promise in treating specific cancer types, particularly high-grade serous ovarian cancer (HGSOC).
Esperas is currently focused on advancing the clinical applications of ESP-001, aimed at addressing critical unmet needs in cancer therapy. The management team, led by CEO Caroline Fortier, is optimistic about the potential of this groundbreaking treatment as they continue to gather data supporting its efficacy and safety.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Canada
The Canadian biotechnology sector is a vibrant component of the global pharmaceutical industry, characterized by its commitment to innovation and research. Canada has established itself as a hub for life sciences wit
Similar Deals
TVM Capital Life Science
invested in
Esperas Pharma, Inc.
in 2023
in a Other VC deal